Crossbow Therapeutics raised $77 million in a Series B round.
- Amount
- $77M
- Stage
- Series B
- Announced
- 18 March 2026
- Leads
- Taiho Ventures, Arkin Bio Capital
- Other investors
- Sixty Degree Capital, Hamilton Square Partners Management LP, LifeLink Ventures, Libbs Ventures, MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Company, Mirae Asset Venture Investment
- Use of funds
- Complete the Phase 1 CBX-250 trial, initiate the CBX-663 Phase 1 trial, and advance other T-Bolt programs.
- Checked
- Amount and date matched across 2 press sources